New MS biosimilar PB018 faces first human test against ocrevus
Disease control
Not yet recruiting
This Phase 1 trial will test PB018, a biosimilar to the MS drug Ocrevus, in 222 people with multiple sclerosis. The study compares how the body processes PB018 versus Ocrevus and checks for safety. Participants will receive either PB018 or Ocrevus, but neither they nor their doct…
Phase: PHASE1 • Sponsor: Polpharma Biologics International AG • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC